PA
SYRE icon

Parallel Advisors’s Spyre Therapeutics SYRE Stock Holding History

Parallel Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.9K Buy
720
+688
+2,150% +$50.2K ﹤0.01% 1976
2026
Q1 		$1.61K Buy
+32
New +$1.21K ﹤0.01% 3437
2025
Q2 		– Sell
-14
Closed -$226 – 3693
2025
Q1 		$226 Buy
+14
New +$291 ﹤0.01% 3361
2024
Q1 		– Sell
-1
Closed -$22 – 3413
2023
Q4 		$22 Buy
+1
New +$14 ﹤0.01% 3277

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Parallel Advisors's SYRE Position: Q2 2026 in Review

Parallel Advisors increased its Spyre Therapeutics (SYRE) stake by 2,150% in Q2 2026, buying an estimated $50.2K and bringing the position to 720 shares worth $63.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1976.

Parallel Advisors first reported a position in SYRE in Q4 2023 and has held it in 4 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Parallel Advisors held 720 shares of Spyre Therapeutics worth $63.9K as of Q2 2026.
  • Parallel Advisors bought 688 Spyre Therapeutics shares in Q2 2026, an estimated $50.2K.
  • Spyre Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #1976 holding.
  • Parallel Advisors first reported a position in Spyre Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.